LJ-001
LJ-001 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped viruses. It acts as an inhibitor which blocks viral entry into host cells at a step after virus binding but before virus–cell fusion, and also irreversibly inactivates the virions themselves by generating reactive singlet oxygen molecules which damage the viral membrane.